Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug

seekingalpha09-17

Hoth Therapeutics (NASDAQ:HOTH) shares rose about 14% premarket after it announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. A recent study on Alzheimer's model...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468099351?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442724/image_1284442724.jpg","is_english":true,"pubTime":"2024-09-17 20:47","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2468099351","market":"hk","top_or_hot":-1,"title":"Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug","media":"seekingalpha","content":"<div>\n<p>Hoth Therapeutics (NASDAQ:HOTH) shares rose about 14% premarket after it announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. A recent study on Alzheimer's model...</p>\n\n<a href=\"https://seekingalpha.com/news/4150287-hoth-therapeutics-stock-climbs-on-promising-preclinical-results-for-its-alzheimers-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-17 20:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4150287-hoth-therapeutics-stock-climbs-on-promising-preclinical-results-for-its-alzheimers-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hoth Therapeutics (NASDAQ:HOTH) shares rose about 14% premarket after it announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. A recent study on Alzheimer's model...</p>\n\n<a href=\"https://seekingalpha.com/news/4150287-hoth-therapeutics-stock-climbs-on-promising-preclinical-results-for-its-alzheimers-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01611","symbol_name":"新火科技控股","start_time":0,"source_url":"https://seekingalpha.com/news/4150287-hoth-therapeutics-stock-climbs-on-promising-preclinical-results-for-its-alzheimers-drug","article_id":"2468099351","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442724/image_1284442724.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468099351","pubTimestamp":1726577234,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Hoth Therapeutics  shares rose about 14% premarket after it announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. A recent study on Alzheimer's model mice treated with different doses of HT-ALZ showed a notable decrease in astrocyte activity in key brain areas, suggesting a link between fewer reactive astrocytes and better cognitive function.  Reactive astrocytes, which are typically larger than normal astrocytes, play a role in the progression of neurodegenerative diseases like Alzheimer's. Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's. Source: Press Release","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"01611":"新火科技控股","HOTH":"Hoth Therapeutics","BK1167":"电子制造服务","BK4007":"制药"},"translate_title":"Hoth Therapeutics的阿尔茨海默病药物临床前结果令人鼓舞，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"01611":0.9},"content_text":"Hoth Therapeutics (NASDAQ:HOTH) shares rose about 14% premarket after it announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. A recent study on Alzheimer's model mice treated with different doses of HT-ALZ showed a notable decrease in astrocyte activity in key brain areas, suggesting a link between fewer reactive astrocytes and better cognitive function.  Reactive astrocytes, which are typically larger than normal astrocytes, play a role in the progression of neurodegenerative diseases like Alzheimer's. Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's. Source: Press Release","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468099351"}